含卡培他滨联合方案一线化疗后卡培他滨维持治疗转移性乳腺癌临床观察  

Clinical observation of capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer

作　　者：童刚领[1] 王芬[1] 陈晓秋[1] 彭安[1] 申东兰[1] 王树滨[1] 

机构地区：[1]北京大学深圳医院肿瘤内科,广东深圳518036

出　　处：《现代肿瘤医学》2014年第9期2118-2120,共3页Journal of Modern Oncology

摘　　要：目的:探讨转移性乳腺癌含卡培他滨联合方案一线化疗后继续卡培他滨维持化疗的疗效和毒副反应。方法:入组20例转移性乳腺癌患者,一线采用多西他赛/吉西他滨/长春瑞滨联合卡培他滨化疗6个周期,疗效评价无进展的患者采用卡培他滨维持化疗持续到疾病进展或出现不能耐受毒副反应为止。结果:一线治疗CR 1例,PR 7例,SD 12例,卡培他滨平均维持化疗周期为10个周期。中位PFS为12.2个月,中位TTP为7.7个月,中位OS为20.2个月。主要毒副反应为手足综合征、骨髓抑制、腹泻等,均可控制。结论:卡培他滨可作为转移性乳腺癌的维持治疗,可改善患者生存,毒副反应轻。Objective:To investigate the curative effect and toxicity of capecitabine maintenance chemotherapy after the first- line capecitabine- based combination chemotherapy for patients with metastatic breast cancer( MBC).Methods:This study enrolled into 20 chemotherapy- naive MBC patients. They received 6 cyceles of docetaxel /gemcitabine /vinorelbine and capecitabine chemotherapy,and patients who responded to the themotherapy were assigned to capecitabine maintenance chemotherapy until disease progression or intolerable toxicity. Results:Patients were evaluated for the first- line therapy efficacy. The patients who acquired CR,PR and SD were 1,7 and 12. The median of ten cycles of the capecitabine maintenance chemotherapy were completed in 20 patients. The median progression free survival time was 12. 2 months. The median time to progression was 7. 7 months. The median overall survival time was20. 2 months. The most common toxicity included hand- foot syndrome,myelosuppression,diarrhea. Conclusion:Capecitabine maintenance chemotherapy is benefit in survival in MBC patients,and with low toxicity.

关 键 词：转移性乳腺癌 卡培他滨 维持化疗 疗效 毒副反应 

分 类 号：R737.9[医药卫生—肿瘤]